Vitiligo News

Patients with vitiligo treated with oral povorcitinib showed significant repigmentation of the face and body, Incyte announced in a press release.

Each year, WHO marks World Mental Health Day on Oct. 10 in an effort to raise awareness of mental health issues around the world and mobilize efforts to support mental health.

Patients with vitiligo have a significantly lower risk for all-cause and cause-specific mortality compared with matched controls, according to a study.

Researchers created a comprehensive guide about the pharmacology, efficacy, safety and patient cost options of topical ruxolitinib for the treatment of nonsegmental vitiligo.

Dermatologists are needed to remedy the increasing incidence of laser complications and educate patients on the risks involved with laser treatment, according to a speaker at the Pigmentary Disorders Exchange Symposium.

The European Commission has approved Opzelura in the European Union to treat nonsegmental vitiligo with facial involvement in patients aged 12 years and older, Incyte announced in a press release.

NEW ORLEANS — Povorcitinib was associated with substantial repigmentation in patients with extensive nonsegmental vitiligo, according to a study presented at the American Academy of Dermatology Annual Meeting.

WAILEA, Hawaii — Research and treatment options for vitiligo have increased exponentially in recent years and promise new developments, according to a speaker at the Maui Derm meeting.

WAILEA, Hawaii — Treating macular dermal hyperpigmentation conditions requires a multi-pronged approach, according to a speaker here.